. . . . . . . "[Currently the utilization of erlotinib with WBRT or SRS is therefore investigational and may be a reasonable option in erlotinib na�ve, EGFR mutated patients with refractory BM.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:12+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .